Strs Ohio Has $723,000 Stock Position in CareDx, Inc (NASDAQ:CDNA)

Strs Ohio lifted its holdings in shares of CareDx, Inc (NASDAQ:CDNA) by 65.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 60,300 shares of the company’s stock after purchasing an additional 23,800 shares during the quarter. Strs Ohio owned approximately 0.11% of CareDx worth $723,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Nisa Investment Advisors LLC increased its stake in shares of CareDx by 442.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 6,440 shares of the company’s stock worth $77,000 after purchasing an additional 5,253 shares during the last quarter. ARK Investment Management LLC increased its stake in shares of CareDx by 7.7% during the 4th quarter. ARK Investment Management LLC now owns 7,194,722 shares of the company’s stock worth $86,337,000 after purchasing an additional 515,399 shares during the last quarter. Raymond James & Associates increased its stake in shares of CareDx by 10.5% during the 4th quarter. Raymond James & Associates now owns 76,837 shares of the company’s stock worth $922,000 after purchasing an additional 7,270 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of CareDx during the 4th quarter worth $259,000. Finally, Public Employees Retirement System of Ohio increased its stake in shares of CareDx by 67.5% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 98,848 shares of the company’s stock worth $692,000 after purchasing an additional 39,843 shares during the last quarter.

CareDx Trading Down 5.3 %

NASDAQ CDNA opened at $7.56 on Friday. The company has a fifty day simple moving average of $9.62 and a 200 day simple moving average of $9.20. The company has a market cap of $391.46 million, a P/E ratio of -2.14 and a beta of 1.42. CareDx, Inc has a 1 year low of $4.80 and a 1 year high of $12.93.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($2.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($1.97). CareDx had a negative net margin of 67.88% and a negative return on equity of 51.40%. The company had revenue of $65.57 million during the quarter, compared to the consensus estimate of $63.66 million. During the same period last year, the company earned ($0.34) earnings per share. CareDx’s revenue for the quarter was down 20.4% on a year-over-year basis. Equities research analysts forecast that CareDx, Inc will post -1.59 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Stephens reaffirmed an “overweight” rating and set a $15.00 price objective on shares of CareDx in a report on Wednesday, April 17th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, CareDx currently has a consensus rating of “Hold” and a consensus price target of $13.50.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.